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Aim: This study compared volumetric-modulated arc therapy (VMAT) plans for head and
neck cancers with and without an external body contour extended technique (EBCT).
Background: Dose calculation algorisms for VMAT have limitations in the buildup region.
Materials and methods: Three VMAT plans were enrolled, with one case having a metal artifact
from an artificial tooth. The proper dose was calculated using Eclipse version 11.0. The body
contours were extended 2 cm outward from the skin surface in three-dimensional space,
and the dose was recalculated with an anisotropic analytical algorithm (AAA) and Acuros
XB  (AXB). Monitor units (MUs) were set, and the dose distributions in the planning target
volume (PTV), clinical target volume, and organ at risk (OAR) and conformity index (CI)
with and without an EBCT were compared. The influence of a metal artifact outside of the
thermoplastic head mask was also compared.
Results: The coverage of PTV by the 95% dose line near the patient’s skin was  increased
drastically by using an EBCT. Plan renormalization had a negligible impact on MUs and
doses  delivered to OARs. CI of PTV with a 6-MV photon beam was closer to 1 than that
with a 10-MV photon beam when both AAA and AXB were used in all cases. Metal artifactsoutside the head mask had no effect on dose distribution.
 is nConclusions: An EBCTpatient’s skin and can im
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.  Background
espite improvements in dose calculation algorithms imple-
ented in radiotherapy treatment planning systems (TPSs)
or calculation dose accuracy in regions of homo- and hetero-
eneity, the limitations in the buildup region have remained,
nd many  investigators have tried to solve them.1–10 Court
t al.4 reported that the agreement between the skin doses
alculated by the pencil beam convolution (PBC) algorithm
n the EclipseTM TPS (Varian Medical systems, Palo Alto, CA,
SA) and measured by the metal oxide semiconductor field
ffect transistor dosimeters was within ±20%. Oinam and
ingh6 evaluated the accuracy of the anisotropic analytical
lgorithm (AAA) in the Eclipse TPS version 8.6 for dose cal-
ulation in the buildup region by comparing the calculated
oses with corresponding doses measured using the ther-
oluminescent dosimeter (TLD). AAA-calculated doses were
ower by 7.56% than the TLD-measured doses at 0.2-cm depth.
ijken et al.10 compared the surface doses measured with a
adiochromic film (RCF) and calculated by the Pinnacle3
®
9.10
Koninklijke Philips N.V., Amsterdam, the Netherlands) using
 thorax phantom immobilized by a vac bag and reported
hat measured surface doses were as much as double those
alculated by the TPS. We  face many  problematic cases in
linical sites suspected to be near skin in intensity-modulated
adiation therapy (IMRT) and volumetric-modulated arc ther-
py (VMAT) for head and neck cancers. In these cases, the
ose prescribed to the primary or nodal target volume would
ot be estimated adequately, as several researchers have
eported that model-based dose calculation algorithms gen-
rally underestimate the doses administered to surface and
uildup regions.4,6 Furthermore, acute skin toxicity caused
y IMRT  for head and neck cancers, such as radiation der-
atitis, erythema, desquamation, and necrosis, has been
 significant concern for radiation oncologists.2,8,11,12 It is
ecessary to develop a technique that can calculate proper
oses to the surface and buildup regions with commercial
PSs.
A simple technique to improve the calculated skin dose
ccuracy in a TPS was reported by Wang et al. as a feasibil-
ty study.13 They showed that the performance of skin dose
alculation with AAA by the Eclipse TPS improves when the
ody contour is extended by 1–2 cm outside the skin: the
atient’s skin dose predicted by Eclipse was brought within
% of the MC-calculated dose by using this simple technique.
he technique enables us to estimate the dose delivered to
bject volumes near the skin surface properly in VMAT for
ead and neck cancers, but the clinical impact of this has not
een researched in past studies. They only investigated the
ose prescribed to the skin and the primary or nodal target
olumes located deep below the skin with a simple tech-
ique for real patient clinical treatment plans in their previous
eport..  Aim
n this study, to address the effectiveness of an external body
ontour extended technique (EBCT), we first compared thetherapy 2 4 ( 2 0 1 9 ) 576–584 577
surface and isocenter doses administered to a phantom calcu-
lated by AAA and AXB with and without an EBCT, as measured
by RCF and an ionization chamber. Then, VMAT plans for head
and neck cancers with and without an EBCT were compared.
The dose distributions to the planning target volume (PTV),
clinical target volume (CTV), and organ at risk (OAR) and the
conformity index (CI) with and without an EBCT were com-
pared by using AAA and AXB not investigated in the previous
study13 in Eclipse TPS version 11.0. The influence of a metal
artifact outside a thermoplastic head mask was also com-
pared.
3.  Material  and  methods
3.1.  Commercial  TPS  and  dose  calculation  algorithms
A commercial TPS (Eclipse version 11.0) was employed in
this study. The dose calculation algorithms were AAA and
AXB with heterogeneity correction. The photon energies were
6 and 10 MV, with flattened beams generated by a Novalis-
TxTM linear accelerator (Varian Medical systems and BrainLAB
A.G., Heimstetten, Germany). The calculation grid size was
2.5 mm.13 The dose reporting mode for AXB was set as dose-
to-medium. The material table version 11.0 was used, and the
material mapping was done automatically.
3.2.  Phantom  study:  comparison  of  the  calculated  and
measured  doses  in  the  surface  and  isocenter  regions
To prepare for the basic experiments, Gafchromic EBT3 film
(Lot No. 11151703; International Specialty Products, Wayne, NJ,
USA) and a 0.6 cm3 farmer chamber (TN30013; PTW, Freiburg,
Germany) were used to measure the doses at the surface
and isocenter of an I’mRT Phantom of size 18 × 18 × 18 cm3
(IBA Dosimetry GmbH, Schwarzenbruck, Germany). Fig. 1 (a)
shows the measurement of the surface dose using a ther-
moplastic head mask (CIVCO Medical Solutions, Kalona, IA,
USA) with thickness of 2.4 mm and an EBT3 film cut to
approximately 12 × 12 cm2 and placed at the central axis on
the proximal phantom surface and sandwiched between the
head mask and the I’mRT Phantom. A 0.6-cm3 farmer cham-
ber was inserted into the center of the I’mRT Phantom to
measure the dose at the isocenter. Photon beams with ener-
gies of 6 and 10 MV from a Novalis-Tx linear accelerator
were delivered at a gantry angle of 0◦ with a field size of
10 × 10 cm2, 200 MUs, and 100-cm source–detector distance
(SDD).
We analyzed the EBT3 film doses according to previous
reports.14,15 An Epson Offirio ES-10000 G (Epson Seiko Cor-
poration, Nagano, Japan) document scanner and FILM SCAN
version 10.3.2 software were used to scan the irradiated films.
The analysis software was the DD-system (DD-Analysis ver-
sion 10.3.1; R-tech, Tokyo, Japan).
Computed tomography (CT) images of an I’mRT Phantom
set inside a thermoplastic head mask, an EBT3 film, and a 0.6-
cm3 farmer chamber were imported into the Eclipse TPS. The
external body contour was constructed manually to surround
the contour of the I’mRT Phantom correctly because thermo-
plastic head masks are not included with it in the clinical
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Fig. 1 – (a) Photograph and (b) axial, sagittal, and coronal CT images of an I’mRT Phantom set inside a thermoplastic head
mask, EBT3 film, and 0.6-cm3 farmer chamber. The CT images contain contoured structures for a 0.6-cm3 farmer chamber,
default body contour, and extended body contour represented by red, green, and yellow lines, respectively.case. A structure representing the sensitivity area of a 0.6-cm3
farmer chamber was also created to calculate the mean doses,
as shown in Fig. 1 (b). We calculated the surface on which the
EBT3 film was placed and the dose at the isocenter as point
and mean doses using AAA and AXB with and without an
EBCT under the same irradiation conditions as those under
which the measurements were obtained. As part of the EBCT
plans, the body contours were placed 2 cm outside the skin
in three-dimensional space by use of the margin tool [Fig. 1
(yellow lines)]. For accurate comparison with the doses to the
EBT3 films, the calculation grid size was set to 1.0 mm for the
basic experiments.
3.3.  VMAT  plans  for  head  and  neck  cancers
Three VMAT  plans for head and neck cancers were investi-
gated in this study. Clinical diseases had infiltrated near the
skin in two cases, and one case had a metal artifact from an
artificial tooth. Each patient characteristic was summarized in
Table 1.
Each CT image  was duplicated, and body contours were
constructed using the body contour tool in Eclipse TPS with
the threshold CT value set to −350 Hounsfield Units (HU).
Gross tumor volumes (GTVs), CTVs, and OARs were copied
from the practical treatment plans. For this study, to evaluate
the dose in the buildup region adequately, we  created the PTVs
by extending the CTV 5 mm outward to the body contour.16,17
Some cases were adjusted to satisfy the dose constraints for
the OARs. The PTV was pulled back 2–3 mm from the skin only
in the VMAT  optimization to prevent boosting of the beamlets.
The planning risk volume (PRV) margins were 3–5 mm for the
spinal cord, brain, brainstem, and optic nerves. The CT value
of soft or muscle tissue with a metal artifact was assigned
as indicated by the relative electron density of water. Fig. 2
shows the axial CT images, including contoured structures,
for all cases.
The prescribed dose was 70 Gy in 35 fractions, and the plan
normalization mode was set so that 100% of the planned dosewas administered to 95% of the PTV for all cases. The VMAT
plans consisting of 2–3 full arcs were created with a 6-MV
photon beam, and the doses were calculated with AAA in the
Eclipse TPS. The Dose volume optimizer version 11.0 was set as
the calculation model for the VMAT optimization. We  refer to
DXX% as the dose or percentage of the prescribed dose to XX%
volume of the structural region in this study, and all VMAT
plans were designed to satisfy the dose constraints for PTV and
OARs following: D98% > 93%, D95% = 100%, and D2%  < 115%
for PTV, maximum dose (DMax) < 125% for all irradiated vol-
umes, DMax < 50 Gy for PRV of the spinal cord, DMax < 50 Gy for
PRV of Brain and Brainstem, mean dose (DMean) < 26 Gy for at
least one side parotid gland, DMax < 40 Gy for the Eye ball, and
DMean < 6 Gy for the Lens.
3.4.  Comparison  of  dose  distributions  with  and
without  an  EBCT  on  CT  images
The proper dose was calculated using an EBCT in all cases.
In the plans described above, the body contours were placed
2 cm outside the skin surface in three-dimensional space by
use of the margin tool [Fig. 2 (yellow lines)], and the dose was
recalculated using AAA and AXB in the Eclipse TPS. A couch
top was not included in the body contour extension in this
study because Wang et al.13 reported that the dose difference
between skin with and without a couch was roughly 1%. First,
the same MUs were set, and the dose distributions of PTV and
CTV with and without an EBCT were compared. The percent-
ages of the PTV receiving at least 95% of the prescribed dose
were calculated and analyzed. D99% for CTV and D98%, D95%,
D50%, D10%, and D2% for PTV were evaluated. Then, the plan
normalization mode was reset so that 100% of the planned
dose was administered to 95% of the PTV in the plan with
an EBCT, and the dose delivered to the OARs was evaluated.
Finally, to assess the adequacy of the photon energy for target
volumes close to the surface, the CI of the PTV with a 6-MV
photon beam was compared with that with a 10-MV photon
beam using an EBCT.
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Table 1 – Summary of the patient and tumor characteristics.
Case No. Diagnosis Stage Tumor volume (cm3)* Tumor site
1 Maxillary sinus cancer III 56.37 Maxillary sinus
2 Hypopharyngeal cancer IVa 60.20 Pyriform sinus
3 Oropharyngeal cancer I 3.87 Palatine tonsil
∗ Values for primary and nodal gross tumor volume.
Fig. 2 – Axial CT images including contoured structures for all cases. Brown, red, blue, green, and yellow lines represent
GTV, CTV, PTV, the default body contour, and the extended body contour, respectively. (a) The first case and (b) the second
case have clinical diseases that extend near the skin, and (c) the third case has a metal artifact from an artificial tooth.
Table 2 – Surface and isocenter doses to an I’mRT Phantom for (a) 6- and (b) 10-MV photon beams measured by EBT3 film
and a 0.6-cm3 farmer chamber and calculated by AAA and AXB with and without an EBCT.
(a)
Measurement With an EBCT Without an EBCT
AAA AXB AAA AXB
Surface dose (Gy) 1.61 0.63 0.71 1.90 1.76
Isocenter dose (Gy) 1.58 1.61 1.61 1.59 1.60
(b)
Measurement With an EBCT Without an EBCT



















Surface dose (Gy) 1.16 0.61
Isocenter dose (Gy) 1.72 1.73
.5.  Evaluation  of  the  influence  of  a  metal  artifact
utside  the  thermoplastic  head  mask
n the case with a metal artifact, we also created the plan by
ssigning the CT value of the air layer outside the thermo-
lastic head mask influenced by the metal artifact to −1000
U. The same MUs  were set, and then dose recalculation was
erformed with AAA and AXB in the Eclipse TPS. The normal-
zation value was reset, and the dose distributions of PTVs and
ARs were compared with those without assignment of the CT
alue.
.  Results
.1.  Results  of  phantom  study:  comparison  of  the
alculated  and  measured  doses  in  the  surface  and
socenter  regions
able 2 indicates the doses to the surface and isocenter of an
’mRT Phantom measured by EBT3 films and a 0.6-cm3 farmer0.56 1.60 1.42
1.74 1.72 1.74
chamber and calculated by AAA and AXB with and without an
EBCT for 6- and 10-MV photon beams. For the 6-MV photon
beam, although the difference of the surface dose between
that measured by an EBT3 film and that calculated by AAA and
AXB without an EBCT was −60.9% and −55.9%, respectively, an
EBCT improved these results by 18.0% and 9.3%, respectively.
About 2.0% of the difference in the isocenter dose between that
measured by a 0.6-cm3 farmer chamber and that calculated by
both AAA and AXB without an EBCT was also ameliorated by
0.6% and 1.3% for AAA and AXB, respectively, by using an EBCT.
The same tendency was observed in the results for the 10-MV
photon beam.
4.2.  Results  of  comparison  of  the  dose  distributions  of
CT scanning  with  and  without  an  EBCTFigs. 3 and 4 show the dose distributions calculated by AAA
and AXB with and without an EBCT for two cases. The dose
distributions described only by a 95% dose line are indicated
in the lower row. The coverage of the PTV by the 95% dose line
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Fig. 3 – Contoured structures and dose distributions painted by a color wash (upper row) and the 95% dose line in orange
o ful(lower row) for the first case. The 6-MV VMAT plans with tw
an EBCT, and (c) AXB with an EBCT.
near the patient’s skin was increased using an EBCT. Table 3
summarizes the percentage of the PTV receiving at least 95%
of the prescribed dose (V95% for the PTV) for both cases. In
the first case, although V95% for the PTV was only 95.8% with
Fig. 4 – Contoured structures and dose distributions painted by t
(lower row) for the second case. The 6-MV VMAT  plans with thre
with an EBCT, and (c) AXB with an EBCT.l arcs calculated by (a) AAA without an EBCT, (b) AAA with
the default body contour, this increased to 99.4% and 98.8%
for AAA and AXB with an EBCT, respectively. Similar results
were obtained in another case. Fig. 5 illustrates the dose vol-
ume  histograms (DVHs) of the PTV by using AAA and AXB with
he color wash (upper row) and the 95% dose line in orange
e full arcs calculated by (a) AAA without an EBCT, (b) AAA
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Fig. 5 – DVHs for the PTV obtained by AAA without an EBCT and AAA and AXB with an EBCT. PTVs from (a) the first case
and (b) the second case.
Table 3 – Results of V95% for PTV calculated by AAA and
AXB with and without an EBCT for the first and second
cases.
First case Second case
V95% for PTV (%) V95% for PTV (%)














Table 4 – Results of the dose-volumetric data for the PTV
and CTV calculated by AAA with and without an EBCT









CTV, D99% (%) 60.9 100.6 99.6
PTV, D98% (%) 71.5 102.2 98.7
PTV, D95% (%) 100.0 104.7 102.7
PTV, D50% (%) 109.4 108.1 107.8
PTV, D10% (%) 112.5 113.6 113.2









CTV, D99% (%) 75.3 100.2 99.6
PTV, D98% (%) 93.4 97.8 96.8
PTV, D95% (%) 100.0 99.7 98.7
PTV, D50% (%) 105.4 104.0 103.3AAA with an EBCT 99.4 99.2
AXB with an EBCT 98.8 98.9
nd without an EBCT for the first and second cases. An EBCT
teepened the slope of the DVHs for both AAA and AXB. Table 4
ists the results of the dose-volumetric data for the PTV and
TV in two cases. In the first case, D99% for CTV and D98%
or PTV were increased by up to 39.6% and 30.7%, respectively,
y using an EBCT. Further, D99% for CTV and D98% for PTV
ere increased by 24.9% and 4.4%, respectively, for AAA with
n EBCT in the second case. There was almost no difference
n other dose-volumetric data from these two cases.
Table 5 summarizes the MUs  and dose-volumetric data in
he OARs after plan renormalization for the plans with an
BCT for the first and second cases. There was almost no dif-
erence in the MUs  and dose-volumetric data in either case.
owever, the maximum dose to the right eyeball was 46.1 Gy
PTV, D10% (%) 108.2 107.7 107.6
PTV, D2% (%) 110.2 110.6 110.4
582  reports of practical oncology and rad
Table 5 – MUs  and dose-volumetric data for OARs after
plan renormalization, calculated by AAA and AXB with











MU 732 700 713
Eyeball (left), DMax (Gy) 36.7 34.6 34.7
Eyeball (right), DMax (Gy) 43.2 40.8 46.1
Lens (left), DMean (Gy) 9.2 8.8 8.9
Lens (right), DMean (Gy) 9.7 9.4 8.7
Optic nerve (left) (PRV),
DMax (Gy)
38.1  35.8 36.6
Optic nerve (right) (PRV),
DMax (Gy)
53.9  50.8 54.3
Brain (PRV), DMax (Gy) 67.6 63.6 65.1











MU 790 793 801
Parotid gland (left), DMedian
(Gy)
15.8  16.0 15.4
Parotid gland (right), DMedian
(Gy)
15.6  15.8 15.3
Parotid gland (left), DMean
(Gy)
24.0  24.1 23.7
Parotid gland (right), DMean
(Gy)
26.7  26.7 26.4
Spinal cord (PRV), DMax (Gy) 45.3 44.9 44.7
test case was 1.09 with a 6-MV photon beam. Our results wereBrain (PRV), DMax (Gy) 47.6 46.9 46.8
Brainstem (PRV), DMax (Gy) 46.8 46.4 46.6
due to the dose increment near areas of low density, and this
violated the general dose constraint for AXB.
In the first case, although the CI values of the PTV with a
6-MV photon beam were 1.11 and 1.09 for AAA and AXB with-
out an EBCT, respectively, an EBCT improved these results by
1.01 and 1.03, respectively. The CI values of the PTV with a 10-
MV  photon beam were 1.09 and 1.11 for AAA and AXB with
an EBCT, respectively, and were more  distant to 1 than those
obtained using a 6-MV photon beam for AAA and AXB with an
EBCT. In the second case, although the CI value of the PTV with
a 6-MV photon beam was 1.10 for both AAA and AXB without
an EBCT, an EBCT improved these results by 1.09. The CI val-
ues of the PTV with a 10-MV photon beam was 1.10 for both
AAA and AXB with an EBCT and were more  distant to 1 than
those obtained using a 6-MV photon beam for AAA and AXB
with an EBCT.
4.3.  The  influence  of  a  metal  artifact  outside  the
thermoplastic  head  mask
Fig. 6 shows the DVHs for the PTV and OARs calculated by AAA
and AXB with and without assignment of the CT value of the
air layer outside the thermoplastic head mask to −1000 HU for
the third case (i.e., the one with the metal artifact). There was
no difference between the dose distributions obtained using
AAA and AXB.iotherapy 2 4 ( 2 0 1 9 ) 576–584
5.  Discussion
In this study, we  investigated the clinical impacts on dose dis-
tribution of applying an EBCT to the clinical VMAT  plan for
head and neck cancers. Figs. 3–4 show that the VMAT  plans
with an EBCT for both AAA and AXB incorporated scattered
radiation from an air layer and the thermoplastic head mask.
Thereby, the coverage of the PTV by the 95% dose line near
the patient’s skin was drastically increased for all cases, and
D99% for the CTV and D98% for the PTV were increased by
up to 39.6% and 30.7%, respectively, in Table 4. Wang et al.13
reported that AAA with the default body contour underesti-
mated the skin dose by more  than 14% of the prescription
dose to avoid including patient immobilization devices in the
calculation volume.2 Their feasibility study showed that this
underestimation could be improved by extending the body
contour to encompass at least 1 cm of the air outside the skin
by comparison with the MC-calculated dose validated using
the optically stimulated luminescence dosimeters. The results
posed a problem for clinical use, however, they did not describe
clinical values because they only illustrated that the DVHs for
the PTVs from the VMAT plan which the primary or nodal
target volumes were located deep below the skin were not
affected by using an EBCT. An EBCT could improve the accu-
racy of the calculated dose to the surface and buildup regions,
especially for problematic cases in which clinical diseases
infiltrate nearby skin and enable us to estimate the proper
dose to the target volume. Proper estimation might reduce
the dose delivered to OARs more  than ever before and pre-
vent radiation toxicity.2,8,11,12 In future work, we  will attempt
to apply an EBCT to more  clinical cases to further verify the
clinical impact on dose distributions.
The doses at deeper target volumes or OARs are not affected
by an EBCT.13 Our results also showed that plan renormaliza-
tion had a negligible impact on the MUs and doses delivered
to OARs. However, re-optimization was not performed for any
of the plans investigated in this study to evaluate clearly the
impact of an EBCT on non-optimized calculations but the
calculation dose accuracy in the VMAT plan for head and
neck cancer whose object volumes are located near patient’s
skin, and the MUs and doses to OARs calculated by AAA
and AXB with an EBCT might not have been evaluated suffi-
ciently. Because the shape of the DVHs for the target volumes
changed significantly, the clinical dose distribution might have
impacted the volume normalization in the IMRT  plan. Fur-
ther, it is necessary to examine a suitable technique for the
optimization in VMAT planning with an EBCT.18,19
An EBCT improved the CI values of the PTVs with a 6-MV
photon beam; especially, those were improved by approxi-
mately 1 for both AAA and AXB in the first case. The reason
for this was that the coverage of the PTV by the 95% dose line
near the patient’s skin was improved significantly by using an
EBCT. Mynampati et al.20 created the American Association
of Physics in Medicine Task Group 119 benchmark plans21 for
the VMAT plan and showed that the CI of the head and neckequal to or better than theirs, and the dose conformity of the
PTVs with a 6-MV photon beam had higher performance than
that with a 10-MV photon beam. However, we  also should
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Fig. 6 – DVHs for PTV and OARs obtained by (a) AAA and (b) AXB with an EBCT in the third case. Solid lines and cross plots























rtifact to −1000 HU.
valuate the dose distributions in the VMAT plan with a 10-
V photon beam in the case of deep-seated head and neck
ancers.
We verified the effects of an EBCT on the calculation of
ose accuracy in the surface and buildup regions through
ur basic experiments (Table 2). An RCF might be suitable to
easure the surface dose: Bilge et al. reported that the surface
oses administered to an EBT film and a Markus parallel plate
onization chamber agreed within 5% for a 6-MV photon
eam.22 However, EBT3 measurement doses converted from
ose-response curves with analog-to-digital converter values
re relative doses that are regarded as an index of the surface
ose.23 Our results showed that an EBCT obviously improved
he accuracy of dose calculation in the surface region by
ncluding a thermoplastic head mask in the body contour, but
he dose difference was still large even if an EBCT was used.
n RCF has several characteristics,15,24,25,26 and Borca et al.25
ndicated that overall uncertainty of 1.7% was observed
ith an EBT3 film. Moreover, surface dose measurements very challenging, and it has been investigated in several
tudies.27–30 The measurement errors with commonly used
etectors (including an RCF) while comparing the surfacedose using the PTW 30–360 extrapolation chamber (PTW,
Freiburg, Germany) ranged from −0.1% to 26% before any
corrections were applied.27 This is a limitation of this study;
new, special dosimeter systems or correction factors for
measurement of the doses in the surface and buildup regions
might be necessary.
6.  Conclusions
An EBCT that uses AAA and AXB as components of the VMAT
plan for head and neck cancers is needed to estimate a proper
dose at object volumes near patient skin and can improve the
accuracy of dose calculation in the target volumes.
Conflict  of  interest

































[30]. Akbas U, Kesen ND, Koksal C, Okutan M, Demir B, Becerir HB.
Surface dose measurement with Gafchromic EBT3 film for
intensity modulated radiotherapy technique. EPJ Web Conf
2017;154 (2017)01011.584  reports of practical oncology an
Acknowledgements
We  thank Richard Lipkin, PhD, from Edanz Group (www.
edanzediting.com/ac) for editing a draft of this manuscript.
 e  f  e  r  e  n  c  e  s
1]. Chung H, Jin H, Dempsey JF, Liu C, Palta J, Suh TS, et al.
Evaluation of surface and build-up region dose for
intensity-modulated radiation therapy in head and neck
cancer. Med Phys 2005;32:2682–9.
2]. Hadley SW, Kelly R, Lam K. Effects of immobilization mask
material on surface dose. J Appl Clin Med Phys 2005;6:
2005.
3]. Court LE, Tishler RB. Experimental evaluation of the impact
of different head-and-neck intensity-modulated radiation
therapy planning techniques on doses to the skin and
shallow targets. Int J Radiat Oncol Biol Phys 2007;69:
607–13.
4]. Court LE, Tishler RB, Allen AM, Xiang H, Makrigiorgos M, Chin
L.  Experimental evaluation of the accuracy of skin dose
calculation for a commercial treatment planning system. J
Appl Clin Med Phys 2008;9:2008.
5]. Panettieri V, Barsoum P, Westermark M, Brualla L, Lax I. AAA
and  PBC calculation accuracy in the surface build-up region
in tangential beam treatments. Phantom and breast case
study with the Monte Carlo code PENELOPE. Radiother Oncol
2009;93:94–101.
6]. Oinam AS, Singh L. Verification of IMRT dose calculations
using AAA and PBC algorithms in dose buildup regions. J Appl
Clin  Med Phys 2010;11:2010.
7]. Kry SF, Smith SA, Weathers R, Stovall M. Skin dose during
radiotherapy: a summary and general estimation technique. J
Appl Clin Med Phys 2012;13:2012.
8]. Lee N, Chuang C, Quivey JM, Phillips TL, Akazawa P, Verhey LJ,
et  al. Skin toxicity due to intensity-modulated radiotherapy
for  head-and-neck carcinoma. Int J Radiat Oncol Biol Phys
2002;53:630–7.
9]. Joseph K, Rose B, Warkentin H, Yun J, Ghosh S, Tankel K.
Peri-anal surface dose in anal canal VMAT radiotherapy. J Med
Imaging Radiat Oncol 2018;62:734–8.
0]. Rijken J, Kairn T, Crowe S, Muñoz L, Trapp J. A simple method
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